LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

DNA Test for Lyme Disease in Horses Could Diagnose Difficult-to-Detect Illnesses in Humans

By LabMedica International staff writers
Posted on 18 Aug 2022
Image: A DNA test that identifies Lyme disease in horses could have applications for humans (Photo courtesy of Unsplash)
Image: A DNA test that identifies Lyme disease in horses could have applications for humans (Photo courtesy of Unsplash)

Lyme disease is the most common vector-borne illness in the U.S., according to the Centers for Disease Control and Prevention (CDC). In humans, a characteristic skin rash may or may not occur, along with fever, headache and fatigue. Unchecked, the infection can move to the nervous system, the joints and the heart. Similar to humans, horses are incidental, dead-end hosts for the disease agent, the corkscrew-shaped bacterium Borrelia burgdorferi, meaning the hosts carry the infection but do not infect others. Lyme disease in horses can cause long-term complications that include damage to the nervous system, joints, skin and even vision. Not all infected horses develop clinical signs of Lyme disease. If symptoms occur, they can include chronic weight loss, lameness and low-grade fever. Antibody tests usually are administered when a Lyme disease infection is suspected. In a new study, an antibody test and a PCR test of a sick 11-year-old Swedish Warmblood mare did not indicate an infection, but an advanced test detected the disease. The ultra-sensitive DNA test could also have applications for difficult-to-detect illnesses in humans such as Lyme disease.

As with the treatment of most diseases, early detection is essential with Lyme. While many illnesses, such as COVID-19 and strep throat, attack humans with many numbers of pathogens, in other diseases, such as Lyme disease, the bacteria slowly reproduce within a host, producing far fewer numbers and making detection more difficult. Scientists at Rutgers University (Newark, NJ, USA) have been working to devise ways to better detect diseases that possess “low copy numbers” of a pathogen.

The scientists devised a special DNA test that helped identify Neurologic Lyme disease in the sick 11-year-old mare. Although Lyme disease was suspected, a standard PCR test did not detect Borrelia burgdorferi. The new “genomic hybrid capture assay” developed by Rutgers scientists is a highly sensitive test that identified the pathogen in a sample of the horse’s spinal fluid, allowing it to be diagnosed and successfully treated. The test works by first selectively isolating DNA from the microorganism causing the disease.

“The method is like having a special, specific ‘fishhook’ that only grabs Borrelia DNA and not the DNA of other microbes, nor the DNA of the host (animal or human),” said Steven Schutzer, a professor of medicine at Rutgers New Jersey Medical School, who devised the test. “Detecting DNA of the disease is a direct test, meaning we know you have active disease if it’s circulating in the blood or spinal fluid.”

Related Links:
Rutgers University

Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
Gold Member
Immunochromatographic Assay
CRYPTO Cassette

Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more